OncoMatch/Clinical Trials/NCT06630234
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Is NCT06630234 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies DCC-3009 for gastrointestinal stromal tumor (gist).
Treatment: DCC-3009 — The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastrointestinal Stromal Tumor
Biomarker criteria
Required: KIT mutation
Required: PDGFRA mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: tyrosine kinase inhibitor — advanced/metastatic
Cannot have received: systemic anticancer therapy
Cannot have received: radiotherapy
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function, bone marrow function, and electrolytes
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- University of Colorado Anschutz Medical Campus · Aurora, Colorado
- Mayo Clinic Florida · Jacksonville, Florida
- University of Miami - Sylvester Comprehensive Cancer Center · Miami, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify